GSK has had a solid start to 2026, with revenues rising ahead of analyst expectations in the first full quarter under new CEO Luke Miels.
AZ will invest £300m in UK, says PM Keir Starmer
AstraZeneca has delivered a much-needed boost to the UK government alongside a strong set of first-quarter results.
